Precision Epigenomics
Precision Epigenomics is a Tucson-based molecular diagnostics company that sells EPISEEK, a $699 blood-based multi-cancer early detection test using proprietary methylation-specific PCR to identify over 60 cancer types, serving health-conscious adults, healthcare providers, and occupational health programs.
- Company typePrivate
- Founded2019
- HeadquartersTucson, United States
- Headcount1–10
- GTM typeB2C
- OfferingServices
What Precision Epigenomics does
Precision Epigenomics is a molecular diagnostics company founded in 2019 and headquartered in Tucson, Arizona, that develops blood-based liquid biopsy tests for multi-cancer early detection. Its core product, EPISEEK, is a $699 blood test that uses proprietary methylation-specific PCR technology to analyze cell-free DNA and detect over 60 cancer types from a single blood draw, with results delivered in 7-10 days. The company also offers EPISEEK-MPE, a pleural-fluid-based variant targeting indeterminate pleural effusions where conventional cytology detects only ~50% of malignancies, and validates its assays through clinical studies including a 281-patient validation cohort presented at ASCO 2025 and a 191-patient EPISEEK-MPE study presented at AMP 2025.
The company operates a CLIA-certified, CAP-accredited laboratory in Tucson and holds a USPTO patent protecting its methylation-specific PCR methodology. Machine learning algorithms analyze amplified methylation signals to generate cancer detection reports, supporting reported performance metrics including 99.5% specificity, 64.9% positive predictive value, and 99.5% negative predictive value. The company extends its platform into research-grade pleural fluid analysis via the NIH-funded EPISEEK-MPE program in collaboration with University of Arizona.
Precision Epigenomics generates revenue through one-time test sales at $699 per EPISEEK unit, distributed via direct-to-consumer online ordering, a clinician ordering portal, an AZOVA Health digital health platform partnership, and occupational health partnerships with Front Line Mobile Health. Tests are not covered by insurance but can be paid via HSA/FSA accounts. The company is pursuing a secondary laboratory licensing revenue stream. Total funding to date exceeds $3.9 million, comprising a $1.5M Series A1 led by Shaffer Capital plus $2.4M in non-dilutive NIH and NCI grants. The company remains privately held with 1-10 employees.
Precision Epigenomics firmographics
Firmographics- Name
- Precision Epigenomics
- Legal name
- Precision Epigenomics Inc.
- Website
- https://precision-epigenomics.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Precision Epigenomics is a Tucson-based molecular diagnostics company that sells EPISEEK, a $699 blood-based multi-cancer early detection test using proprietary methylation-specific PCR to identify over 60 cancer types, serving health-conscious adults, healthcare providers, and occupational health programs.
- Ownership category
- akta.pro rank
Precision Epigenomics industry classification
Industry- Product category
- Molecular Cancer Diagnostics
- NAICS
- Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Testing Laboratories (8734)
- akta.pro primary industry
- Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG)
- akta.pro secondary industries
- Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes) (HLAAAMAH), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)
Keywords
Where Precision Epigenomics is headquartered
LocationHeadquarters
- HQ city
- Tucson
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Precision Epigenomics business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- EPISEEK Test Sales: One-time payment of $699 per test sold directly to consumers and through healthcare providers. Single transaction model without recurring revenue from individual tests.
- Laboratory Licensing: Licensing revenue from laboratory expansion strategies, enabling other facilities to offer EPISEEK testing using company's proprietary technology and protocols.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Single EPISEEK MCED Test |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels7 records
Precision Epigenomics product offering
Product offeringCore offering
Precision Epigenomics develops and sells the EPISEEK Multi-Cancer Early Detection (MCED) blood test, which uses proprietary methylation-specific PCR analysis of cell-free DNA to detect hypermethylated DNA loci associated with over 60 cancer types. The test is sold direct-to-consumer and through physician orders at $699 per test, processed at the company's CAP-accredited, CLIA-certified laboratory in Tucson, Arizona, with results delivered in 7-10 days.
Product overview
Precision Epigenomics offers a unified portfolio centered on its EPISEEK® liquid biopsy platform for multi-cancer early detection. The core offering is the EPISEEK MCED Blood Test, a methylation-based multi-cancer detection assay that analyzes cell-free DNA from blood to detect over 60 cancer types. The platform extends to EPISEEK-MPE, a specialized version analyzing pleural fluid for malignancy classification in patients with pleural effusion. All tests are processed through the company's CAP-accredited, CLIA-certified laboratory in Tucson, Arizona, with results typically available within 7-10 days for the blood test and 2-3 days for validated assays. The company offers direct-to-consumer ordering through licensed healthcare providers at $699 per test.
Differentiator
Problem solved
Functional benefit
Brands
- EPISEEK: Multi-cancer early detection (MCED) blood test that uses a simple blood draw to identify DNA changes linked to over 60 types of cancer by detecting hypermethylated DNA loci.
- EPISEEK-MPE
- EPISEEK-MCED
Products and services
- EPISEEK Multi-Cancer Early Detection (MCED) Blood Test A blood-based multi-cancer detection test that uses methylation-specific PCR to analyze cell-free DNA from a simple blood draw, detecting hypermethylated DNA loci associated with over 60 cancer types including lung, liver, pancreatic, brain, and esophageal cancers. Results are available in 7-10 days and the test is sold direct-to-consumer at $699 and through physician orders. It is intended for health-conscious adults aged 45 and over, individuals at higher risk, healthcare providers, and employer wellness programs.
- EPISEEK-MPE (Multi-Cancer Early Detection using Pleural Fluid) A methylation-specific PCR assay that detects tumor-derived cell-free DNA directly in pleural fluid using only 10 mL of sample. It is designed to improve cancer detection in pleural effusion cases where conventional cytology has approximately 50% sensitivity, providing diagnostic clarity for indeterminate cases and statistically significant prognostic value for predicting 24-month survival (p < 0.005).
Quantifiable outcome
- 45% incidence-adjusted sensitivity for early-stage (Stage I-II) cancers
- +5 more outcomes
Companies that use Precision Epigenomics
Customer profileNamed customers3 records
Segments5 records
Ideal customer profiles5 records
Precision Epigenomics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature3 records
Precision Epigenomics partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- University of ArizonacoreStrategic partnership with University of Arizona for EPISEEK-MPE (Multi-Platform Epigenomics) development as part of NIH grant project. Collaboration leverages university research capabilities and genomics expertise.
- AZOVA HealthcoreStrategic alliance to make EPISEEK MCED test available nationwide through AZOVA's digital health platform, expanding distribution reach through telehealth and digital health channels.
- Front Line Mobile HealthcorePartnership to deliver EPISEEK to first responders in Texas, Colorado, and Georgia through occupational health programs. Provides channel distribution for targeted customer segment.
- Midwestern UniversityminorCollaboration on EPISEEK-MPE study, supporting clinical validation and research development of the multi-platform epigenomics technology.
Scale indicators2 records
Recent moves6 records
Expansion highlights6 records
Precision Epigenomics competitors and assessment
Company assessmentDirect peers
- GRAIL: GRAIL's Galleri is a leading blood-based multi-cancer early detection test using methylation analysis of cell-free DNA, directly competing with EPISEEK in the MCED category for asymptomatic screening adults.
- Natera: Natera is a molecular diagnostics company with cfDNA-based tests including Signatera (MRD) and EmpowerDX, overlapping with Precision Epigenomics in liquid biopsy technology and cancer screening.
- Freenome: Freenome is developing a multiomics blood test for early cancer detection using cfDNA and other analytes, directly competing with EPISEEK in the blood-based MCED screening category.
Broad incumbents
- Exact Sciences: Exact Sciences (Cologuard, Oncotype DX, and the Thrive/CancerSEEK acquisition) is a major publicly-traded diagnostics company expanding into multi-cancer screening, competing with EPISEEK in physician-channel cancer detection.
- NeoGenomics: NeoGenomics is an established oncology-focused clinical laboratory offering molecular and genetic testing services, comparable to Precision Epigenomics' CAP-accredited clinical lab business model in cancer diagnostics.
- Guardant Health: Guardant Health is an established liquid biopsy company (Guardant360, Shield) extending into multi-cancer screening applications, using cell-free DNA analysis comparable to EPISEEK's approach.
Regional players
- Burning Rock Biotech: Burning Rock is a China-based next-generation sequencing oncology diagnostics company offering liquid biopsy cancer tests, providing a regional comparable in cfDNA-based cancer detection technology.
Emerging players
- Adela: Adela is developing a cell-free DNA methylation-based multi-cancer detection platform using novel sequencing approaches, directly comparable to Precision Epigenomics' methylation-specific PCR MCED strategy.
- Personalis: Personalis is a cancer genomics company offering liquid biopsy-based MRD and tumor profiling tests that overlap with EPISEEK's cfDNA methylation analysis technology for oncology applications.
- Delfi Diagnostics: Delfi Diagnostics uses cell-free DNA fragmentation patterns for cancer detection, an emerging blood-based cancer screening approach that competes with EPISEEK's methylation-specific PCR technology.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Precision Epigenomics social profiles
Digital presencePrecision Epigenomics compliance and trust
Trust signalCompliance2 records
Precision Epigenomics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Precision Epigenomics leadership team
Management profileNumber of profiles
Profiles9 records
Precision Epigenomics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Precision Epigenomics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Precision Epigenomics
What does Precision Epigenomics do?
Precision Epigenomics develops and sells the EPISEEK Multi-Cancer Early Detection (MCED) blood test, which uses proprietary methylation-specific PCR analysis of cell-free DNA to detect hypermethylated DNA loci associated with over 60 cancer types. The test is sold direct-to-consumer and through physician orders at $699 per test, processed at the company's CAP-accredited, CLIA-certified laboratory in Tucson, Arizona, with results delivered in 7-10 days.
Is Precision Epigenomics a public or private company?
Precision Epigenomics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Precision Epigenomics founded?
Precision Epigenomics was founded in 2019. It employs 1 to 10 people.
Where is Precision Epigenomics based?
Precision Epigenomics is headquartered in Tucson, United States, in the North America region.
How does Precision Epigenomics make money?
Two revenue lines are on record. EPISEEK Test Sales are the primary driver. The others are laboratory Licensing.
Who are Precision Epigenomics's main competitors?
Direct peers on record are GRAIL, Natera and Freenome. Broad incumbents are Exact Sciences, NeoGenomics and Guardant Health. Burning Rock Biotech is listed as a regional player. Emerging players are Adela, Personalis and Delfi Diagnostics.
Does Precision Epigenomics have an API?
No public API is recorded for Precision Epigenomics.
What industry is Precision Epigenomics in?
Precision Epigenomics's product category is Molecular Cancer Diagnostics. Its primary akta.pro industry code is HLAAANAG, Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing, with a secondary code of HLAAAMAH, Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes). Its NAICS code is 621511 and its SIC code is 2835.